Back to news

Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business

Globe Newswire•19/11/2026•16:05 ET
0

Key Highlights

  • ➤Stockholders approve Standard BioTools’ merger with Treeline Biosciences
  • ➤Stockholders approve sale of Mass Cytometry business to Element Biosystems
  • ➤Treeline merger expected to close in fourth quarter of 2026
  • ➤Mass Cytometry sale expected to close substantially concurrently with merger

Expert Statements

Michael Egholm, President and Chief Executive Officer of Standard BioTools

“We are pleased with the outcome of today’s vote and thank our stockholders for their support of these transactions.”

Michael Egholm, President and Chief Executive Officer of Standard BioTools

“These approvals represent an important step toward completing our planned merger with Treeline and positioning our Mass Cytometry business for continued success under new ownership.”

Michael Egholm, President and Chief Executive Officer of Standard BioTools

“We look forward to completing both transactions.”

BOSTON, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced that, at its Special Meeting of Stockholders held earlier today, stockholders approved all proposals related to the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”) and the sale of its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC.

“We are pleased with the outcome of today’s vote and thank our stockholders for their support of these transactions,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “These approvals represent an important step toward completing our planned merger with Treeline and positioning our Mass Cytometry business for continued success under new ownership. We look forward to completing both transactions.”

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in